Lancet publishes results from a randomized, placebo-controlled, double- blinded trial of remdesivir (in combination with other medicines, including LPV/r, interferons, and corticosteroids) in people hospitalized with severe COVID-19. No significant differences in adverse events, viral clearance, time to recovery or mortality rates were reported, although the study was unable to reach full enrollment due to Wuhan’s waning epidemic. Source